Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin by Schneider, D. P. et al.
Annals of Oncology 10. 677-683. 1999.
© 1999 Khmer Academic Publishers. Printed in the Netherlands.
Original article
Long-term evolution of renal function in patients with ovarian cancer after
whole abdominal irradiation with or without preceding cisplatin*
D. P. Schneider,1 H.-P. Marti,2 C.Von Briel,1 F. J. Frey2 & R. H. Greiner1
1
 Department of Radiation Oncology. 2Division of Nephrology, University of Bern. Inselspital, Bern. Switzerland
Summary
Background: The upper limit of the natural decline in creati-
nine clearance is 1 ml/min/year. To define the loss of renal
function, we started a long-term assessment of patients with
ovarian cancer treated by whole abdominal irradiation (WAI)
with preceding cisplatin chemotherapy (CDDP) and second-
look laparotomy (SLL).
Patients and methods- We analyzed the creatinine clearance
over time of 56 patients treated from 1982 to 1988 for ovarian
cancer. Thirty-one of 56 patients had received WAI after their
initial surgery, and 25 of 56 patients had undergone CDDP
therapy followed by SLL, and then WAI after their initial
surgery. Median follow-up was 99 months (7-156). Twenty of
56 patients accepted our invitation for additional assessment
of tubular function, nine of the 31 patients without CDDP
therapy and SLL, and 11 of the 25 patients with CDDP
followed by SLL and WAI.
Ten of twenty patients had received four to six cycles
CDDP, 80 mg/m2/cycle, and one patient nine cycles. The
median total dose for each kidney was 1450 cGy (480-1690).
Results: The mean creatinine clearance decreased from 84
ml/min to 66 ml/min. Seventy-six percent of the 25 patients
who had undergone CDDP therapy, SLL and WAI had de-
clines of more than 1 ml/min/year, 64% of these patients of
more than 2 ml/min/year. For the 31 patients who had re-
ceived WAI after their initial surgery, the corresponding num-
bers were 71% and 55%, respectively. The tubular function of
the 20 patients who had undergone the additional investiga-
tions was not impaired.
Conclusion: The decline in renal function after WAI is more
pronounced than in healthy subjects. The treatment with cis-
platin and SLL prior to WAI does not seem to contribute to
this loss of kidney function.
Key words: cisplatin (CDDP), nephrotoxicity, ovarian cancer,
whole abdominal irradiation (WAI)
Introduction
Adverse effects of irradiation on kidneys were first dis-
cussed by Baerman et al. in 1904 [1]. In 1952 and 1964,
Kunkler and Luxton described clinical syndromes of
radiation nephropathy by the analysis of patients treated
for seminoma [2, 3]. Many patient reports of renal
disorders after irradiation subsequently followed in
rapid sequence [4-18]. Hallmarks of chronic radiation
nephropathy are arterial hypertension, glomerular scle-
rosis/hyalinization, fibrinoid changes in arterioles and
interlobular arteries, tubular atrophy and interstitial
fibrosis [19].
A task force under the direction of the National
Cancer Institute defined tolerance doses of various organs
and tissues to therapeutic irradiation and published
their recommendations in 1991 [20]. To support these
recommendations, further systematic clinical studies are
warranted. Cassady stressed in a recent article the need
for well designed studies with long follow-up periods to
accurately assess late radiation toxicity [21].
In this context, we examined the radiation nephrop-
athy of our patients with advanced and non-advanced
ovarian cancer who were treated in controlled protocols
by surgery followed by either CDDP, second-look
laparotomy and WAI or WAI exclusively following sur-
gery. The long-term assessment examined especially the
impact and mutual influence of the two potentially
nephrotoxic agents, CDDP and irradiation, sequentially
given, on renal function.
Patients and methods
From 1982 to 1988, a total of 136 patients, aged 14 to 82 years, all with
epithelial ovarian cancer, were treated by surgery followed by either
cisplatin (CDDP), second-look laparotomy and WAI. or by WAI
alone. Of these 136, nine foreign patients were lost to follow-up, and
71 died sometime after therapy. 67 of causes related to the ovarian
cancer; none, however, suffered from kidney failure.
Study group
The remaining 56 patients comprised our study group. The median
follow-up period was 99 months (7-156). Twenty of 56 patients agreed
* The first and second author contributed equally to the present investigation.
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Table 1 Characteristics of the 20 investigated patients.
Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Age at study
begin
49
60
57
42
46
57
53
30
65
49
44
51
33
53
60
53
37
45
65
62
Observation
period (years)
7
9
6
12
10
10
9
13
10
8
5
9
11
12
11
12
10
6
12
9
CDDP(mg)
4 x 140
5 x 130
4 x 140
5 x 120
4 x 150
5 x 130
4 x 140
9 x 8 5
6 x 120
5 x 140
4 x 140
_
—
_
-
_
—
—
-
-
Radiation
technique
for WAI
OF
OF
OF
MS
OF
OF
OF
MS
OF
OF
OF
OF
MS
MS
MS
OF
MS
OF
MS
OF
Single kidney
doses (Gy)
0.65
0.65
0 65
1 15
0.65
0.65
0.65
1.15
0.65
0.65
0.65
0.65
1.15
1.15
1.15
0.65
1.15
0.65
1.15
0.65
Total kidney
doses (Gy)
10.20
12 80
16.20
14.50
15.00
11.80
15.00
14.50
15.00
4.80
16.90
15.00
14.50
14.50
14.50
11.00
14.50
15 00
14.50
15 00
C O at study
begin/end
(ml/min)
81/67
83/29
84"/67
85/84
112/51
83/46
87"/49
92/78
64/59
95"/74
79/78
93"/64
IOOa/67
81-/52
68"/37
77"/49
78a/71
H6a/52
74a/43
81"/49
Diabetes mellitus or
hypertension
_
H°
-
-
DM
H
-
-
H
H
H
-
-
-
H
-
-
-
-
DM
Abbreviations: CDDP - cis-diamminedichloride platinum; WAI - whole abdominal irradiation; CC1 - creatinine clearence. values followed by "
were calculated according to Cockcroft et al. [22] or Jeliffe et al. [23]; OF - open field; MS - moving strip: DM - diabetes mellitus, H -
hypertension (H° = in addition to hypertension, history of excessive consumption of phenacetin).
to undergo investigaton of renal-tubular function in addition to assess-
ment of glomerular filtration rate. These 20 patients constituted the
investigated group, while the remaining 36 patients formed the non-
investigated group.
In the investigated group, 11 of 20 patients (FIGO stage: 2 x IC. 1 x
IIB, 2 x IIC, 6 x HI) had received CDDP chemotherapy, 10 patients
four to six cycles with 80/m2/cycle and 1 patient nine cycles. In
addition to CDDP as the only nephrotoxic agent, combination chemo-
therapy contained either melphalan, melphalan and hexamethylmela-
min, or cyclophosphamide. The FIGO stage of the nine investigated
patients without CDDP chemotherapy were 5 x IB/C, 2 x MB, and 2 x
III. In the non-investigated group 14 of 36 patients received CDDP
chemotherapy (FIGO stage: 3 x IC. 5 x 2B/C. and 6 x III). The FIGO
stage of the 22 patients in the non-investigated group who did not
receive CDDP chemotherapy were 21 x IB/C, and 1 x III.
For the investigation of a possible adverse effect of cisplatin on
renal function, we pooled patient data from the investigated (n = 20)
and non-investigated (;; = 36) patients and classified these individuals
into two new groups, WAI patients treated with cisplatin (/; = 25) and
those receiving no cisplatin chemotherapy (;J = 31). Median age and
follow-up periods for the former group were 52 years (28-72) and 83
months (26-156). respectively, and for the latter group 53 years (33-82)
and 102 months (7-148). respectively.
Kidney irradiation dose
To deliver whole abdominal irradiation (WAI), the moving strip and.
later, the open field techniques were used. Patients were treated in
prone position using anterior-posterior fields for a target volume
extending from the domes of the diaphragms to the lower border of
the obturator foramina: 5 H.V.L. lead shielding were inserted to shield
the kidneys from the posterior field. Kidney shielding was localised by
an intravenous pyelogram at the time of treatment simulation. Cobalt-
60 beam was employed for the moving strip technique. The single dose
was 230 cGy adapted to an isodose. which encompassed the whole
abdomen rather homogeneously. For the open field technique the
energies of 8 or 16 MeV from the linear accelerator were used. The
single dose of 130 cGy was calculated for mid-plane. The median total
kidney dose for both techniques was 14.5 Gy (4.8-16.9 Gy) with single
kidney doses in the range of 1 15 Gy (moving strip) and of 0.65 Gy
(open field). Terminations of treatment, principally because of hemato-
toxicity, are the reason for the broad range of the kidney doses.
Study group: Investigated patients (n = 20)
The median age of the investigated group at diagnosis was 52 years
(30-65). All 20 patients were tumor-free at the time of the study. The
median follow-up period of these patients was 117 months (61-156).
Additional clinical data and details of radiation and chemotherapy are
given in Table 1. Analyses of all 20 patients included clinical history,
physical examination, blood and urine tests and kidney ultrasound. At
the end of the observation period, 24-hour urine specimens were
collected from all patients in order to determine creatinine clearance,
proteinuria. and tubular function by excretion of uric acid, phosphate
and glucose. Urine analysis including measurement of pH for assess-
ment of tubular acidification was performed in random morning urine
samples. Prior to any therapy such as WAI or chemotherapy, creatinine
clearance was measured from 24-hour urine specimens in eight pa-
tients. For the remaining 12 patients, the creatinine clearance was
calculated using the formulas reported by Cockcroft et al. [22] and
Jelliffe et al. [23]. To predict creatinine clearance, the former relies on
serum creatinine. body weight and age. and the latter on serum
creatinine and age only. In our analyses, we used the first formula,
except in a few patients with significant obesity (body mass index
>30 kg/m2), in whom we applied the second formula because of
overestimation of creatinine clearance by inclusion of excessive body
weight into the calculations.
Study group: Non-investigated patients (n = 36)
The median age of the non-investigated group at diagnosis was 57
years (28-72). Twenty-three of the 36 patients were tumor-free at the
time of the renal function investigations. The median follow-up period
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Figure 1 Creatinine clearance as a function of time in 25 patients
treated with CDDP and WAI. The dashed line indicates the natural
age-related decline of the creatinine clearance (1 ml/year) according to
Bjornsson [24]. A total of 76% of the patients had a decline greater
than 1 ml/year, and 64% of more than 2 ml/year.
140
120- -
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Figure 2. Creatinine clearance as a function of time in 31 patients
treated with WAI only. The dashed line represents the natural decrease
of the creatinine clearance with age (1 ml/year), according to Bjorns-
son [24]. A total of 71% of the patients demonstrated a decline greater
than 1 ml/year, and 55% of more than 2 ml/year.
of these patients was 81 months (7-158) Creatinine clearance values
were calculated in all of these patients, as stated above.
Kidney function
Kidney function in all 56 patients of both the investigated and the
non-investigated groups was analyzed as a function of time. In addition,
the evolution of the glomerular filtration rate in these patients was
compared to the age-related, natural decline in creatinine clearance
[22-27] Importantly, according to Bjornsson et al [24], creatinine
clearance in adults, such as our study patients, decreases by approx-
imately 1 ml/min/year independent of gender. This value was used as
reference for the analyses of our patients.
Results
General evolution of glomerular filtration rate
The main purpose of this study was to investigate the
glomerular filtration rate as a function of time after
WAI. In our 56 patients the decline in creatinine clear-
ance was more pronounced than in healthy subjects
during an identical observation period. The mean crea-
tinine clearance in our patients decreased by 18 ml/min
(from 84 ± 16 to 66 ± 21 ml/min; P < 0.05) during the
median and mean observation period of eight years.
Effect of CDDP and WAI versus WAI alone on glomerular
filtration rate
During the study period, the decline in mean creatinine
clearance of patients exposed to CDDP and irradiation
(n = 25) was 19 ml/min, very close to the 16 ml/min in
patients treated by radiotherapy alone (n = 31), when a
comparable observation time was considered. Addition-
ally, the results of the creatinine clearances of these two
patient groups were plotted against time (Figures 1 and
2). As shown in Figure 1, 19 of 25 (76%) of the patients
in the group treated with chemotherapy and irradiation
had declines in creatinine clearance greater than 1
ml/year (with 1 ml/year as the natural decline in renal
function of a normal adult population of comparable
age; 24). Moreover, 16 of 25 (64%) of these patients had
losses of more than 2 ml/year. In the group with irradi-
ation alone, the numbers were 71% and 55%, respec-
tively (Figure 2).
Effect of CDDP and WAI on kidney function of the
investigated patient group
Kidney function in the 20 patients in the investigated
group was analyzed in greater detail with respect to
glomerular filtration rate, kidney size, and renal tubular
function. Relevant data of patients, treatment methods
and laboratory results are summarized in Tables 1 and 2.
Glomerular filtration rate. Altogether, during the follow-
up period of 117 months (61-156), the mean creatinine
clearance significantly decreased from 86 ± 13 ml/min
to 58 ± 15 ml/min (P < 0.05), with a mean value for the
patients with CDDP and WAI of 62± 16 ml/min and for
the patients with WAI alone 54 ±11 ml/min. At the end
of the observation period, 11 of the 20 patients demon-
strated creatinine clearances below 60 ml/min; in 9 of
these 11 patients, creatinine clearance was 40-59 ml/min,
and in the remaining two, 39 and 29 ml/min.
In these 20 patients, we were not able to correlate
renal radiation dose and decline in kidney function on
the basis of the data reported in Table 1.
Tubular function. Renal tubular function of the 20
investigated-group patients was analyzed in detail. The
results are summarized in Table 2.
Tubular reabsorption of phosphate (TRP) measured in
individuals with normal renal function (creatinine clear-
ance) was previously reported by Popovtzer et al. to be
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Table 2. Renal tubular function of the 20 investigated patients.
Patients Potassium Magnesium Glucosuria Proteinuria FEU R
(3.5-4.7 mmol/1) (0.70-0.95 (<2.80mmol/ (<0.15g/ (6%-12%)
mmol/l) 24 hours) 24 hours)
TRP%(85%) pH in
spot
urine
Group of patients treated with CDDPand WAI
1
2
3
4
5
6
7
8
9
10
11
Mean (1-1 l ) a
oup of patients tn
12
13
14
15
16
17
18
19
20
Mean (12-20)
3.9
3.6
4.6
4.3
4.3
4.4
4.8
3.7
3
4
3.8
4.0 ±0.5
eated with WAI only
4 4
3.6
4 2
5.3
4.2
3.8
4
4.5
4
4.2 ±0.5
0.78
0.62
1.06
0.82
0.68
0.78
0.92
0.75
0.7
0.74
0.75
0.78 ±0.12
0.78
0.75
0.83
0.76
0.74
0.54
0.81
0.94
0.75
0.77 ±0.11
0
0
0
0
1049
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185
<0.15
0.25
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
< 0 15
< 0 15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
<0.15
7.6
136
13.5
13.1
18.3
9.2
6.4
19
16.3
11.4
8.7
12.5 ±4.1
11.5
10.6
10 1
9
11 4
13.3
8.8
14.4
20.7
12.2 ±3.5
86
70
84
77
73
78
66
76
73
87
76
77 ±6
68
63
71
63
78
-
79
79
76
72 ±6
3
5
5
5
5
5
5.5
5
5
5
6.5
5
5
5
5
5
5
5
5
5
All biochemical results were obtained at the end of the observation period.
a
 Patients 1-11 received WAI and additional chemotherapy as depicted in Table 1
FEur (%): Fractional excretion of uric acid = "™^d£ZL x 100.
TRP: Tubular reabsorption of phosphate = I — fractional excretion of phosphate.
in the order of 85% [28]. In our 20 patients, TRP was
77% ± 6% in the 11 cases treated with CDDP and WAI
and 72% ± 6% in the 9 individuals treated with radio-
therapy alone. Considering reduced mean creatinine
clearances of 62 ± 16 ml/min in the former and of 54 ±
11 ml/min in the latter group, the small reduction in
TRP due to the increase in fractional excretion of phos-
phate is an expected finding according to Popovtzer et
al. [28]. Thus, the small reduction in TRP due to in-
creased fractional phosphate excretion merely reflects
the reduction in renal function and may in addition be
interpreted as a consequence of mild secondary hyper-
parathyroidism.
The fractional excretion ofuric acid (FEur) was 12.5%
± 4.1% in patients treated with CDDPand 12.2% ± 3.5%
in patients not exposed to chemotherapy. These results
are not significantly different from the normal excretion
of uric acid, which is generally on the order of 6% to
12% of the filtered load [29] and 12.0% ± 2.9% in non-
pregnant women [30]. However, as renal function dete-
riorates, there is a progressive increase in excretion and
a relative clearance of uric acid because of increased
tubular secretion of urate and incomplete reabsorption
of filtered urate [31]. According to a plot of glomerular
filtration rate versus FEur by Calabrese et al. [32], both
mean values of FEur obtained in our patient subgroups
are only slightly above the expected value of about 11%:
however, in that publication 10% was considered to be
the upper limit of a normal FEur in unimpaired kidney
function.
Except in the two patients with known diabetes melli-
tus, no glucosuria due to tubular damage was found.
Only one patient showed a slight proteinuria of 0.25 g/day,
which may well be explained by hypertension and past
abuse of phenacetin. In 18 of the 20 patients, a pH of 5.0
was measured in random urine samples. Although this
finding does not entirely exclude an acidification defect
[33], a significant distal renal tubular disorder with
respect to acid excretion seems unlikely.
Finally, potassium and magnesium measured in serum
were in the normal range except in one patient with a
potassium of only 3.0 mmol/1 (3.5-4.7 mmol/1) and in
three patients with borderline to mild hypomagnesemia
of 0.54-0.68 mmol/1 (0.70-0.95 mmol/I). These findings
satisfactorily excluded tubulopathy with loss of electro-
lytes, typically found in cisplatin- induced nephropathy.
Kidney size. The kidney length found in normal adult
females is slightly less than 11 cm [34]. However, renal
length decreases by 2 cm between the ages of 50 and 80
years [35]. Therefore, as measured by ultrasound in the
investigated group, renal size was practically not affected,
with a mean of 10.0 ± 1.1 cm in the CDDP-treated group
and of 10.3 ± 1.1 cm in the group with radiotherapy
alone. Most likely, the only minimal reduction of kidney
size reflected the glomerular function slightly reduced
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Table 3. Patient reports of radiation nephropathy.
Author, year [Ref.]
Luxton. 1964 [3]
Thompson. 1971 [17]
Arneil, 1974 [4]
Keane, 1976 [12]
Churchill, 1978 [6]
Le Bourgeois, 1979 [15]
Birkhead, 1979(5]
Kim, 1984 [13]
Willet. 1986 [18]
Markoe. 1989 [44]
Dewitt, 1990 [7]
Flentje, 1993 [9]
Irwin, 1996 [36]
Schneider [present study]
Patient
number
2.54
2.67
2.2
2.2
2.1
1.74
2.17
1 18
2.86
2.12
2.26
2.142
1.60
56
Underlying disease
Mostly seminoma
Gastric
hypersecretion
Nephro-blastoma
Ovarian carcinoma
Testicular
carcinoma
Lymphoma
Hodgkin
lymphoma
NHL
Abdominal
carcinoma,
lymphoma and
sarcoma
Ovarian cancer,
lymphoma,
lesticular tumor
NHL, Hodgkin
lymphoma, ovarian
cancer, seminoma
Seminoma
Ovarian cancer.
NHL, carcinoid
Ovarian cancer
Total kidney dose
(Gy)
25-30
15-20 to left kidney
15/20 to not
nephrectomized
kidney
25 and 27 to both
kidneys
38 to both kineys
15-45 to left kidney
40 to left kidney
22-45 to one
kidney
26-61 to one
kidney
17-25 to both
kidneys
17-40 (uni-and
bilateral)
19-28 to both
kidneys
19 (7-23) to both
kidneys
14.5 (5-17) to both
kidneys by WAI
Chemotherapy
Not reported
Not given
Actinomycin D
and vincristine
Not given
Bleomycin and
vinblastine
Not reported
Only for 1 patient
reported
Not reported
Not reported
Not reported
Not reported
Not reported
Not given
Cisplatin to 25/56
pat. prior WAI
Follow-up (years)
=£14
8-19
2
10 and 11 months
9 months
3-5
3-6
2-8
3(1-9)
0.5-14
3-5
8(2-21)
9 (5-20)
8(0.5-13)
Kidney function
(GFR)
ARN:20. and
CRN: 22 patients
RN: 31 patients
(9 deaths)
ARN: 2 patients
ESRD and
CClof30ml/min
ARN
(CCI: 67 ml/min)
Stable renal
function
Stable renal
function
RN: 9 patients
(CCI 5216 ml)
Mean decrease of
CC1= 17/min
CRN: 1 patient
(CCI- 48 ml/min)
5 patients with
25% decline of
CCI
'Clinical manifest'
CRN: 7 patients
Stable renal
function
Decrease in mean
CCL from 84 to
66 ml/min
Abbreviations: ARN - acute radiation nephritis. CRN - chronic radiation nephritis: NHL - non-Hodgkin's lymphoma: CCL - creatinine
clearance; ESRD - end-stage renal disease.
over many years and present at the observation time.
Even in the two patients with the lowest creatinine
clearances of 29 ml/min and 37 ml/min, kidney length
was still close to 9 cm. These findings confute pre-existing
chronic renal failure. In addition, renal ultrasound ex-
amination revealed no further pathological findings
such as increased echogenicity, cortical atrophy or pa-
renchymal cysts in any of the 20 patients.
Comorbidity. Co-morbid conditions were found in eight
of the patients in this group which could potentially have
an adverse effect on kidney function, as shown in Table 2.
Arterial hypertension was treated in six patients, includ-
ing the one with excessive consumption of phenacetin,
for durations of five months to six years. However, the
mean creatinine clearances of hypertensive and normo-
tensive patients were almost identical: 54 ml/min and
60 ml/min, respectively. Two patients suffered from
diabetes mellitus. Only one patient with hypertension,
who also had the worst renal function of the 20 patients
analyzed, showed borderline proteinuria of 0.25 g/24 h
(patient 2, Table 1). In addition, this patient was the
only one who demonstrated significant abnormality in
urinalysis, namely microhematuria.
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Discussion
Radiation nephritis is a well-known entity which is,
however, difficult to analyze quantitatively because of
many confounding variables. The key findings of 13
previously published studies or case reports are sum-
marized in Table 3. The observed effects of irradiation on
renal function are heterogeneous, depending on total
renal dose, irradiated renal volume, on uni- or bilateral
kidney irradiation, and on length of patient follow-up
periods. The duration of the present study is extensive
and the patient numbers high, comparable to only four
other studies (Table 3) [3, 9, 17, 36].
Chemotherapy is a common variable in the assess-
ment of radiation nephritis, and chronic renal failure is
a rare but well-described complication of cisplatin [37-
39]. Remarkably, there is no published report separately
analyzing the effects of chemotherapy on the course of
radiation nephropathy, so our study is thus unique with
respect to its direct comparison of irradiated patients
treated with and without cisplatin. However, we found
no differences with respect to cisplatin. Experimental
studies analyzing mice or rats clearly demonstrated an
enhancing effect of cisplatin on kidney damage caused by
irradiation [40-43]. In addition, second-look laparotomy
had no negative effect on renal function in the patients
who received chemotherapy.
Other important confounding factors are hypertension
and diabetes mellitus. As in most other studies, the
precise adverse effects of these two underlying diseases
on kidney function in our subjects is difficult to judge,
since the durations and treatments of hypertension and
diabetes mellitus are not known. Tn addition, high blood
pressure in our patients may be a result of radiation
nephropathy but could also represent essential hyper-
tension, especially in the presence of well-preserved
kidney function, such as in the study patients 10 and 11
(Table 1). However, there were no cases of malignant
hypertension and in our investigated-patient group kidney
function did not differ in hypertensive and normotensive
individuals.
The decline of renal function in our population was
pronounced despite the low single doses of 0.65 and
1.15 Gy. The decrease of the mean glomerular filtration
rate in our 56 patients was more than twice the expected
natural age-related decline of 1 ml/min/year [24].
In addition to creatinine clearance, we analyzed several
factors reflecting renal tubular functions. Despite the
reduction of glomerular filtration rate, renal tubular
function was well preserved. Therefore, most of the late-
effect damage of low-dose irradiation to the kidney may
have occurred to endothelial cells present in arterioles
and in glomerular capillaries rather than to tubular cells
due to interstitial inflammation [13].
In summary, we found no patients with chronic radi-
ation nephropathy in our series of 56 patients who
received WAI or CDDP and SLL followed by WAI after
epithelial ovarian cancer surgery. Nevertheless, analyses
of kidney function over time showed a more pronounced
decline of creatinine clearance in our patients than in
the normal population. Interestingly, the addition of
cisplatin and SLL did not adversely influence the de-
crease in renal function.
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